Amneal Pharmaceuticals, Inc.
AMRXAmneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
Drugs in Pipeline
9
Phase 3 Programs
9
Upcoming Catalysts
1
Next Catalyst
Aug 4, 2026
26dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How AMRX's past catalysts played out
Phenazopyridine Hydrochloride Tables, USP 200 mg
Uncomplicated Urinary Tract Infections
Testosterone Topical Gel, 1.62% Metered Pump
Primary Hypogonadism
Estradiol Vaginal Tablets 10 mcg
Atrophic Vaginitis Due to Menopause
Asenapine Sublingual Tablets 10 mg
Schizophrenia
Imatinib Mesylate Tablets, 400 mg
Chronic Myeloid Leukemia
Phenazopyridine Hydrochloride
Pain
Mometasone Furoate Nasal Spray, 50 mcg
Seasonal Allergic Rhinitis
Test - Bimatoprost 0.01% Ophthalmic Solution
Glaucoma, Open-Angle
Diclofenac Sodium Topical Gel, 1%
Osteoarthritis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Phenazopyridine Hydrochloride Tables, USP 200 mg | Phase 3 | Uncomplicated Urinary Tract Infections | - | - |
Testosterone Topical Gel, 1.62% Metered Pump | Phase 3 | Primary Hypogonadism | - | - |
Estradiol Vaginal Tablets 10 mcg | Phase 3 | Atrophic Vaginitis Due to Menopause | - | - |
Asenapine Sublingual Tablets 10 mg | Phase 3 | Schizophrenia | - | - |
Imatinib Mesylate Tablets, 400 mg | Phase 3 | Chronic Myeloid Leukemia | - | - |
Phenazopyridine Hydrochloride | Phase 3 | Pain | - | - |
Mometasone Furoate Nasal Spray, 50 mcg | Phase 3 | Seasonal Allergic Rhinitis | - | - |
Test - Bimatoprost 0.01% Ophthalmic Solution | Phase 3 | Glaucoma, Open-Angle | - | - |
Diclofenac Sodium Topical Gel, 1% | Phase 3 | Osteoarthritis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Amneal Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 9 drug candidates in Amneal Pharmaceuticals, Inc.'s (AMRX) pipeline across Phase 3. Its lead program is Phenazopyridine Hydrochloride Tables, USP 200 mg (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Amneal Pharmaceuticals, Inc.'s next FDA catalyst?→
Amneal Pharmaceuticals, Inc.'s (AMRX) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AMRX biotech catalysts?→
Add AMRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Amneal Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.